Janux Therapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies using its proprietary TRACTr (Tumor Activated T Cell Engager), TRACIr (Tumor Activated Immunomodulator), and ARM (Adaptive Immune Response Modulator) platforms. Lead clinical candidates include JANX007 (PSMA TRACTr for mCRPC), JANX008 (EGFR TRACTr for solid tumors), and JANX011 (CD19-ARM for autoimmune diseases). The company also has strategic research collaborations with Merck and Bristol Myers Squibb targeting cancer.
Q2 FY2026 — expected 2026-09-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001193125-26-076918 | EDGAR | 103K words |
| 2025-02-27 | 2024-12-31 | 0000950170-25-029177 | EDGAR | 102K words |
| 2024-03-08 | 2023-12-31 | 0000950170-24-028659 | EDGAR | 99K words |
| 2023-03-10 | 2022-12-31 | 0000950170-23-007311 | EDGAR | — |
| 2022-03-18 | 2021-12-31 | 0000950170-22-004171 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001193125-26-338078 | EDGAR | 67K words |
| 2025-11-06 | 2025-09-30 | 0001193125-25-269799 | EDGAR | 67K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-105069 | EDGAR | 66K words |
| 2025-05-08 | 2025-03-31 | 0000950170-25-067083 | EDGAR | 64K words |
| 2024-11-06 | 2024-09-30 | 0000950170-24-122370 | EDGAR | 65K words |
| 2024-08-07 | 2024-06-30 | 0000950170-24-092857 | EDGAR | 66K words |
| 2024-05-08 | 2024-03-31 | 0000950170-24-054966 | EDGAR | 62K words |
| 2023-11-07 | 2023-09-30 | 0000950170-23-060288 | EDGAR | 65K words |
| 2023-08-08 | 2023-06-30 | 0000950170-23-039898 | EDGAR | 65K words |
| 2023-05-09 | 2023-03-31 | 0000950170-23-019689 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0000950170-22-024511 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0000950170-22-016082 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-06 | 0001193125-26-337977 | EDGAR | 2K words |
| 2026-02-26 | 0001193125-26-076627 | EDGAR | 2K words |
| 2026-01-22 | 0001193125-26-019520 | EDGAR | 1K words |
| 2025-11-06 | 0001193125-25-269518 | EDGAR | 2K words |
| 2025-09-19 | 0001193125-25-209259 | EDGAR | 1K words |
| 2025-08-07 | 0000950170-25-105010 | EDGAR | 2K words |
| 2025-06-13 | 0000950170-25-086284 | EDGAR | 1K words |
| 2025-05-08 | 0000950170-25-066969 | EDGAR | 2K words |
| 2025-02-27 | 0000950170-25-029165 | EDGAR | 2K words |
| 2024-12-05 | 0001193125-24-271578 | EDGAR | 1K words |
78 total filings indexed. 51 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001817713 |
| Ticker | JANX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.januxrx.com |
| Listed | 2021-06-11 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/JANX (~200 tokens, structured JSON with cryptographic provenance)